C vs MYGN · P/E 16, rev $85.22B vs rev $837.6M
Citigroup Inc. (C) versus Myriad Genetics Inc (MYGN) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
C currently screens at market cap $214.73B and trailing P/E 15.5. MYGN currently screens at market cap $413.7M.
Not investment advice. Open the C and MYGN stock pages for the full models.
Not investment advice.